Corvus Pharmaceuticals, Inc. (CRVS)
| Market Cap | 160.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.78M |
| Shares Out | 42.25M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 252,822,104 |
| Open | 3.78 |
| Previous Close | 2.26 |
| Day's Range | 2.26 - 5.80 |
| 52-Week Range | 1.86 - 5.80 |
| Beta | 1.67 |
| Analysts | Strong Buy |
| Price Target | 5.13 (-3.6%) |
| Est. Earnings Date | Oct 28, 2021 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lympho...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price forecast is 5.13, which is a decrease of -3.57% from the latest price.
News
Best Penny Stocks to Buy Right Now? 3 You Need to Know About
These penny stocks shot up today, are they worth watching or not? The post Best Penny Stocks to Buy Right Now?
What's Going On With Corvus Pharmaceuticals Stock Today?
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by AstraZeneca PLC (NASDAQ: AZN) for pati...
12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (CRVS) as Shares Rocket
Corvus Pharmaceuticals (CRVS) stock is rising higher on heavy trading volume Friday despite a lack of news from the company. The post 12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (...
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will partici...
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China
Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021 Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021
Down 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
BURLINGAME, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial res...
Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in re...
Corvus Pulls Plug On Mupadolimab COVID-19 Program With Candidate Now Prioritized In Oncology
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has discontinued its Phase 3 study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering infection and hospitalizations....
Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectivenes...
Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies in an expansion cohort for patients with HPV+ (human papil...
Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtua...
Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program
BURLINGAME, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximate...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
BURLINGAME, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial re...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
BURLINGAME, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial re...
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BURLINGAME, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will partici...
The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced u...
Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today
Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-...
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offeri...
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public...
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory f...
Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Ann...
Updated interim d ata from CPI-818 's p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas
Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exp...
Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) Includes updated data from CPI-818 phase 1/1b trial and pre-...
Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC An...
Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2